Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Interleukin-17 Inhibitor in Combination With Tumor Necrosis Factor α Inhibitor in the Treatment of Ankylosing Spondylitis

NCT06833112 is registered in ClinicalTrials.gov with The Affiliated Hospital Of Guizhou Medical University as lead sponsor.

NCT NCT06833112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06833112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Interleukin-17 Inhibitor in Combination With Tumor Necrosis Factor α Inhibitor in the Treatment of Ankylosing Spondylitis
Lead sponsor
The Affiliated Hospital Of Guizhou Medical University
Phase
Phase 4
Overall status
Not yet recruiting
Start date
February 28, 2025
Completion date
February 29, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis